The present study results were in agreement with the three existing systematic review and meta-analyses and suggested that overexpressed EGFR could act as a biomarker of unfavorable OS and DFS in nasopharyngeal carcinoma patients. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.